Search

Your search keyword '"Hung, C-T."' showing total 319 results
Start Over Author "Hung, C-T."
319 results on '"Hung, C-T."'

10. An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours.

Author

Zhi J., Kramer D., Chan W.-K., Hung C.-T., Kwan M.-F.R., Jackson C.G.C.A., Deva S., Bayston K., McLaren B., Barlow P., Hung N.A., Clarke K., Segelov E., Chao T.-Y., Dai M.-S., Yen H.-T., Cutler D., Zhi J., Kramer D., Chan W.-K., Hung C.-T., Kwan M.-F.R., Jackson C.G.C.A., Deva S., Bayston K., McLaren B., Barlow P., Hung N.A., Clarke K., Segelov E., Chao T.-Y., Dai M.-S., Yen H.-T., and Cutler D.

Abstract

Background: Paclitaxel has poor oral bioavailability due to excretion by P-glycoprotein (P-gp) on intestinal cells. Oral paclitaxel may reduce IV access, avoid risks of allergic reaction to cremophor, forego steroid premedication, reduce hospital stay, and improve patient convenience. Oraxol (Athenex, USA) is a combination of oral paclitaxel and HM30181, a novel orally active, potent and specific inhibitor of P-gp with minimal or undetectable systemic exposure. We report the results of a bio-equivalence study of Oraxol compared to IV paclitaxel. Method(s): An international randomized crossover pharmacokinetic (PK) study using HM30181 15mg plus oral paclitaxel 205mg/m2 was given on days 1-3 and compared to a single dose of IV paclitaxel (80 mg/m2) in patients with advanced solid tumors. PK blood samples were taken days 1-9 for oral paclitaxel and days 1-5 for IV paclitaxel. Result(s): 44 patients were randomized. 35 patients were evaluable. The first cohort included 6 patients as a feasibility study. The second cohort included 29 patients and showed: [Table presented] Conclusion(s): Oraxol (oral paclitaxel + HM30181) given daily for 3 days can show bio-equivalence to single dose of IV paclitaxel 80mg/m2 at 80% power with 90% CI of the GMR within the limits of 80 - 125%. Clinical trial identification: ACTRN 12615000894594. Legal entity responsible for the study: Athenex. Funding(s): Athenex. Disclosure: C.G.C.A. Jackson: Travel / Accommodation / Expenses: Athenex. N.A. Hung: Shareholder / Stockholder / Stock options, Full / Part-time employment: Zentech. D. Cutler: Shareholder / Stockholder / Stock options, Full / Part-time employment: Athenex. D. Kramer: Full / Part-time employment: Athenex. J. Zhi: Full / Part-time employment: Athenex. W. Chan: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Athenex. M.R. Kwan: Leadership role, Travel / Accommodation / Expenses, Full / Part-time employment: Athenex. C. Hung

Published
2020

11. An international randomized cross-over bio-equivalence study of oral paclitaxel 1 HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours.

Author

Zhi J., Hung N.A., Clarke K., Segelov E., Chao T.-Y., Dai M.-S., Yen H.-T., Cutler D., Kramer D., Chan W.-K., Hung C.-T., Kwan M.-F.R., Jackson C.G.C.A., Deva S., Bayston K., McLaren B., Barlow P., Zhi J., Hung N.A., Clarke K., Segelov E., Chao T.-Y., Dai M.-S., Yen H.-T., Cutler D., Kramer D., Chan W.-K., Hung C.-T., Kwan M.-F.R., Jackson C.G.C.A., Deva S., Bayston K., McLaren B., and Barlow P.

Abstract

Background: Paclitaxel has poor oral bioavailability due to excretion by P-glycoprotein (P-gp) on intestinal cells. Oral paclitaxel may reduce IV access, avoid risks of allergic reaction to cremophor, forego steroid premedication, reduce hospital stay, and improve patient convenience. Oraxol (Athenex, USA) is a combination of oral paclitaxel andHM30181, a novel orally active, potent and specific inhibitor of P-gp with minimal or undetectable systemic exposure. We report the results of a bio-equivalence study of Oraxol compared to IV paclitaxel. Method(s): An international randomized crossover pharmacokinetic (PK) study using HM30181 15mg plus oral paclitaxel 205mg/m2 was given on days 1-3 and compared to a single dose of IV paclitaxel (80 mg/m2) in patients with advanced solid tumors. PK blood samples were taken days 1-9 for oral paclitaxel and days 1-5 for IV paclitaxel. Result(s): 44 patients were randomized. 35 patients were evaluable. The first cohort included 6 patients as a feasibility study. The second cohort included 29 patients and showed: Conclusion(s): Oraxol (oral paclitaxel + HM30181) given daily for 3 days can show bioequivalence to single dose of IV paclitaxel 80mg/m2 at 80% power with 90% CI of the GMR within the limits of 80 - 125%.

Published
2020

13. MECHANOTRANSDUCTION IN BONE CELL NETWORKS

Author

GUO, X. E., primary, TAKAI, E., additional, JIANG, X., additional, XU, Q., additional, WHITESIDES, G. M., additional, YARDLEY, J. T., additional, HUNG, C. T., additional, and COSTA, K. D., additional

Published
2007
Full Text
View/download PDF

19. An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours

Author

Jackson, C G C A, primary, Deva, S., additional, Bayston, K., additional, McLaren, B., additional, Barlow, P., additional, Hung, N.A., additional, Clarke, K., additional, Segelov, E., additional, Chao, T.-Y., additional, Dai, M.-S., additional, Yen, H.-T., additional, Cutler, D., additional, Kramer, D., additional, Zhi, J., additional, Chan, W.-K., additional, Kwan, M -F R, additional, and Hung, C.-T., additional

Published
2019
Full Text
View/download PDF

29. Animal models of cartilage repair

Author

Cook, J. L., primary, Hung, C. T., additional, Kuroki, K., additional, Stoker, A. M., additional, Cook, C. R., additional, Pfeiffer, F. M., additional, Sherman, S. L., additional, and Stannard, J. P., additional

Published
2014
Full Text
View/download PDF

31. Aerodynamic properties of biohazardous aerosols in hospitals

Author

Fang, M., Lau, A.P.S., Chan, Chak Keung, Hung, C. T., Lee, T. W., Fang, M., Lau, A.P.S., Chan, Chak Keung, Hung, C. T., and Lee, T. W.

Abstract

1. Knowledge of the aerodynamic properties of biohazardous aerosols is important for infection control. 2. The aerosol dynamics involved in coughing and cough-related phenomena are complicated, poorly understood, and require further study. 3. Mature atmospheric aerosol measurement technologies can be used to study aerosols in hospital or clinical environments. This greatly enhances the understanding of the transmission of infectious diseases.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results